Therapeutic drug monitoring data = a...
Dasgupta, Amitava, (1958-)

FindBook      Google Book      Amazon      博客來     
  • Therapeutic drug monitoring data = a concise guide /
  • 紀錄類型: 書目-電子資源 : Monograph/item
    正題名/作者: Therapeutic drug monitoring data/ Amitava Dasgupta, Matthew D. Krasowski.
    其他題名: a concise guide /
    作者: Dasgupta, Amitava,
    其他作者: Krasowski, Matthew D.,
    出版者: London, United Kingdom ;Academic Press, : 2020.,
    面頁冊數: 1 online resource.
    附註: 6.2 Drug-herb interactions
    內容註: Front Cover; Therapeutic Drug Monitoring Data: A Concise Guide; Copyright; Contents; Preface; Chapter 1: Pharmacokinetics and therapeutic drug monitoring; 1.1 Introduction; 1.2 Compliance and TDM; 1.3 Basic pharmacokinetics; 1.3.1 Liberation; 1.3.2 Absorption; 1.3.3 Distribution; 1.3.4 Binding of drugs with serum proteins; 1.3.5 Metabolism; 1.3.6 Excretion; 1.3.7 Pharmacokinetic calculations; 1.3.8 Clearance; 1.4 Therapeutic ranges; 1.5 Guidelines for TDM; 1.6 Specialpopulation and TDM; 1.6.1 Drug disposition in uremia; 1.6.2 Drug disposition in hepatic disease
    內容註: 1.6.3 Drug disposition in cardiovascular diseases1.6.4 Drug disposition in critically ill patients; 1.6.5 Drug disposition in thyroid diseases; 1.7 Conclusions; References; Chapter 2: Before and after: The pre-analytical and post-analytical phases of TDM; 2.1 Introduction; 2.2 Proper timing of specimen collection; 2.3 Issues with blood collection tubes; 2.4 Processing and storage of specimens; 2.5 Troubleshooting; References; Chapter 3: Clinical utility of monitoring free drug levels; 3.1 Introduction; 3.2 Binding of drugs with serum proteins
    內容註: 3.3 Drugs requiring free drug monitoring3.4 When to monitor free drug concentration?; 3.5 Monitoring free anticonvulsant concentration; 3.5.1 Clinical utility of monitoring free phenytoin concentrations; 3.5.2 Clinical utility of monitoring free valproic acid concentration; 3.5.3 Clinical utility of monitoring free carbamazepine concentrations; 3.6 Drugs bound to alpha-1-acid glycoprotein and free drug monitoring; 3.7 Monitoring free concentrations of immunosuppressants; 3.8 Monitoring free concentrations of protease inhibitors; 3.9 Special situation: Monitoring free digoxin
    內容註: 3.10 Saliva for monitoring of free drug concentration3.11 Methods for monitoring free drug concentration; 3.12 Conclusions; References; Chapter 4: Effects of bilirubin, lipemia, hemolysis, paraproteins and heterophilic antibodies onimmunoassays for therapeu ... ; 4.1 Introduction; 4.2 Bilirubin interferences in immunoassays used for TDM; 4.3 Interference due to hemolysis; 4.4 Lipid interference; 4.5 Interferences from protein and paraproteins; 4.6 Interferences from heterophilic antibodies; 4.7 Biotin interferences in TDM; 4.8 Conclusions; References
    內容註: Chapter 5: Application of chromatographic techniques for therapeutic drug monitoring5.1 Introduction; 5.2 Limitations of immunoassays; 5.3 Overview of chromatographic methods; 5.4 High-performance liquid chromatography methods; 5.5 Gas chromatography methods; 5.6 Liquid chromatography coupled to mass spectrometry; 5.7 Challenges with liquid chromatography tandem mass spectrometry systems; 5.8 Therapeutic drug monitoring applications; 5.9 Future directions; References;Chapter 6: Drug-herb and drug-food interactions and effects on therapeutic drug monitoring; 6.1 Introduction
    標題: Drug monitoring. -
    電子資源: https://www.sciencedirect.com/science/book/9780128158494
    ISBN: 9780128158500 (electronic bk.)
館藏地:  出版年:  卷號: 
館藏
  • 1 筆 • 頁數 1 •
 
W9406671 電子資源 11.線上閱覽_V 電子書 EB RM301.9 .D37 2020 一般使用(Normal) 在架 0
  • 1 筆 • 頁數 1 •
多媒體
評論
Export
取書館
 
 
變更密碼
登入